NanoDetection Technology™, Inc. (NDT) has developed a novel, sensitive, rapid, easy-to-use and cost-effective point-of-care in vitro diagnostic test platform system for potentially lethal pathogens, DNA and biomarkers.  These pathogens include those found in healthcare settings (e.g., MRSA, UTI bacteria, etc.), the food chain (e.g., E. coli, Salmonella, and Listeria), and those used in bioterrorism (e.g., anthrax, ricin, etc.).

Charles Barnett M.D. founded NDT in 2002 in Knoxville Tennessee.  Dr. Barnett, who currently serves as the company’s Chief Scientific Officer, licensed the original intellectual property, which forms the basis of NDT’s technology, from the U.S. Department of Energy based on research conducted at Oak Ridge National Laboratories.  The company has since developed its own intellectual property based on recent research and development.  In 2010, CincyTech, a public-private organization whose mission it is to invest in high-growth startup technology companies in Southwest Ohio, brought the company to Cincinnati.

The mission of NDT is to manufacture and sell rapid pathogen detection systems to the healthcare, food safety, and bioterrorism markets worldwide.  These markets are all poised for growth based on the development of new technology that allows faster and more cost-effective methods of pathogen detection. Since the basis of the NDT technology is a diagnostic detector that is independent of the pathogen being tested (a platform system), the company is developing multiple pathogen assays for multiple markets.